Show simple item record

dc.contributor.authorGonzález Salvatierra, Sheila
dc.contributor.authorMartínez Heredia, Luis
dc.contributor.authorMuñoz Torres, Manuel Eduardo 
dc.contributor.authorRiquelme Gallego, Blanca
dc.date.accessioned2021-05-21T08:11:29Z
dc.date.available2021-05-21T08:11:29Z
dc.date.issued2021
dc.identifier.citationGonzález-Salvatierra, S.; García-Fontana, C.; Andújar-Vera, F.; Grau-Perales, A.B.; Martínez-Heredia, L.; Avilés-Pérez, M.D.; Hayón-Ponce, M.; Iglesias-Baena, I.; Riquelme-Gallego, B.; Muñoz-Torres, M.; et al. Osteoglycin as a Potential Biomarker of Mild Kidney Function Impairment in Type 2 Diabetes Patients. J. Clin. Med. 2021, 10, 2209. https://doi.org/jcm10102209es_ES
dc.identifier.urihttp://hdl.handle.net/10481/68606
dc.description.abstractOsteoglycin (OGN) could be a biomarker of mild kidney function impairment in type 2 diabetes (T2D). Our study aimed to determine the association between serum OGN and impaired kidney function risk in T2D patients and to analyze its potential role as an estimator of kidney disturbances in this population. This cross-sectional study included 147 T2D patients (65 ± 8 years, 58.5% males), and 75 healthy controls (63 ± 10 years, 36% males). Circulating OGN levels were determined by ELISA. Linear regression modeling was performed to determine the variables influencing circulating OGN, and an ROC curve was plotted to assess the usefulness of OGN as an estimator of diabetic kidney disease risk. Circulating OGN was significantly increased in T2D patients compared to controls (18.41 (14.45–23.27) ng/mL vs. 8.74 (7.03–12.35) ng/mL; p < 0.001). We found a progressive increase in serum OGN according to the severity of kidney impairment in T2D patients (normal kidney function: 16.14 (12.13–20.48) ng/mL; mildly impaired kidney function: 19.15 (15.78–25.90) ng/mL; moderate impaired kidney function: 21.80 (15.06–29.22) ng/mL; p = 0.006). Circulating OGN was an independent estimator of mildly impaired kidney function risk in T2D patients. We suggest that serum OGN could act as an albuminuria-independent biomarker of incipient kidney dysfunction in T2D patients.es_ES
dc.description.sponsorshipJunta de Andalucía grants (PI-0207-2016 and PI0268-2019)es_ES
dc.description.sponsorshipInstituto de Salud Carlos III grants (PI18-00803 and PI18-01235)es_ES
dc.description.sponsorshipEuropean Regional Development Fund (FEDER)es_ES
dc.description.sponsorshipInstituto de Salud Carlos III (FI19/00118; CD20/00022)es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectBiomarkeres_ES
dc.subjectDiabetic kidney diseasees_ES
dc.subjectKidney function impairmentes_ES
dc.subjectType 2 diabeteses_ES
dc.subjectOsteoglycines_ES
dc.titleOsteoglycin as a Potential Biomarker of Mild Kidney Function Impairment in Type 2 Diabetes Patientses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doijcm10102209


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record

Atribución 3.0 España
Except where otherwise noted, this item's license is described as Atribución 3.0 España